Last edition
News about "pre-clinical programme "
Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases
Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.
Pre-clinical Programme | 31/10/2025 | By Dineshwori | 129
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy